Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964518 | 0.89 | HTR2C (0.34) | MAPK1CYP1A2HTR2CHTR2AHTR2B | |
| SCHEMBL2975585 | 0.89 | MAPK1 (0.41) | MAPK1CYP1A2HTR2CHTR2AALDH1A1 | |
| SCHEMBL2959907 | 0.79 | CYP1A2 (0.39) | MAPK1CYP1A2HTR2CHTR2AALDH1A1 | |
| SCHEMBL2962283 | 0.78 | MAPK1 (0.39) | MAPK1CYP1A2HTR2CHTR2AHTR2B | |
| SCHEMBL2976847 | 0.76 | RAPGEF4 (0.35) | MAPK1CYP1A2ALDH1A1EDNRBEDNRA | |
| SCHEMBL2963096 | 0.76 | TP53 (0.35) | MAPK1CYP1A2HTR2CHTR2AALDH1A1 | |
| SCHEMBL2962936 | 0.75 | HTR2C (0.35) | HTR2CHTR2AHTR2BALDH1A1 | |
| SCHEMBL2971514 | 0.74 | ALDH1A1 (0.39) | MAPK1CYP1A2ALDH1A1EDNRBEDNRA | |
| SCHEMBL2959658 | 0.74 | PBRM1 (0.38) | HTR2CHTR2AHTR2BALDH1A1 | |
| SCHEMBL2973694 | 0.74 | CYP1A2 (0.35) | MAPK1CYP1A2EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | MAPK1 3118/4885CYP1A2 2409/4885HTR2C 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.